Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Optune System Clear all
Active, not recruiting Phase 2 Interventional Results available

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

NCT03405792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, WHO Grade IV
Interventions
Temozolomide (TMZ), Optune System, Pembrolizumab
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 5:00 AM EDT
Terminated Not applicable Interventional

NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01954576
View directory record Official record
Conditions
Glioblastoma, Brain Neoplasms
Interventions
NovoTTF-100A, Quality-of-life assessment, Laboratory biomarker analysis
Device · Procedure · Genetic
Lead sponsor
University of Florida
Other
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 22, 2026, 5:00 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

NCT04396860
View directory record Official record
Conditions
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
Procedure · Biological · Device + 3 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
285
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 22, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

NCT02343549
View directory record Official record
Conditions
Cancer of Brain and Nervous System
Interventions
NovoTTF100A, Bevacizumab, Temozolomide
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 22, 2026, 5:00 AM EDT
Completed Phase 1 Interventional Results available

HUMC 1612: Optune NovoTTF-200A System

NCT03128047
View directory record Official record
Conditions
High Grade Glioma, Ependymoma
Interventions
Optune NovoTTF-200A System
Device
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
5 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Orlando, Florida • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 22, 2026, 5:00 AM EDT
Completed Phase 2 Interventional

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

NCT02847559
View directory record Official record
Conditions
Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Interventions
Bevacizumab, Electric Field Therapy, NovoTTF-200A Device, Quality-of-Life Assessment
Biological · Procedure · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Santa Monica, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 5:00 AM EDT
Active, not recruiting Not applicable Interventional

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

NCT03033992
View directory record Official record
Conditions
Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
Device · Combination Product
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 22, 2026, 5:00 AM EDT
Withdrawn Phase 2 Interventional

NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer

NCT02425072
View directory record Official record
Conditions
Small Cell Lung Cancer, Brain Metastasis
Interventions
NovoTTF-100A plus chemotherapy
Device
Lead sponsor
John Villano
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 22, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

NCT02663271
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
Interventions
Bevacizumab, Optune, Brain MRI, Quality of Life Questionnaires
Drug · Device · Other
Lead sponsor
University of Florida
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 22, 2026, 5:00 AM EDT